Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUl 14	FSTA enhanced with Japanese patents
NEWS	14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAplus enhanced with more pre-1907 records

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:38:13 ON 18 SEP 2006

=> file reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.21 | 0.21

FILE 'REGISTRY' ENTERED AT 15:38:24 ON 18 SEP 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 SEP 2006 HIGHEST RN 907180-17-0
DICTIONARY FILE UPDATES: 17 SEP 2006 HIGHEST RN 907180-17-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer be available. Please contact CAS Customer Care (http://www.cas.org/supp.html) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10790288\Struc 1.str



chain nodes :
7 8 15 16 17 18 19 20 21 22 23 24 27 28
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
chain bonds :
6-7 7-8 7-15 8-9 8-17 15-16 16-27 17-18 17-24 18-19 19-20 20-21 21-22
22-23 27-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
16-27 17-18 17-24 22-23 27-28
exact bonds :
6-7 7-8 7-15 8-9 8-17 15-16 18-19 19-20 20-21 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



10790288.trn

Structure attributes must be viewed using STN Express query preparation.

```
=> l1
SAMPLE SEARCH INITIATED 15:38:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED         1 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            1 TO       80
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> l1 full
FULL SEARCH INITIATED 15:38:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       45 TO ITERATE

100.0% PROCESSED        45 ITERATIONS                               6 ANSWERS
SEARCH TIME: 00.00.01

L3            6 SEA SSS FUL L1

=> file medline caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     167.15

FILE 'MEDLINE' ENTERED AT 15:38:53 ON 18 SEP 2006

FILE 'CAPLUS' ENTERED AT 15:38:53 ON 18 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> l3
L4            4 L3

=> d ibib abs hitstr 1-4

L4   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2006:14820  CAPLUS
DOCUMENT NUMBER:          144:260959
TITLE:                    Identification of a trace colored impurity in drug
                          substance by preparative liquid chromatography and
                          mass spectrometry
AUTHOR(S):                Wang, Peng; Shi, Y.-J.; Helmy, Roy; Reamer, Robert;
                          Vailaya, Anant
CORPORATE SOURCE:         Analytical Research, Merck Research Laboratories,
                          Rahway, NJ, 07065, USA
SOURCE:                   Rapid Communications in Mass Spectrometry (2005),
                          19(24), 3749-3754
                          CODEN: RCMSEF; ISSN: 0951-4198
PUBLISHER:                John Wiley & Sons Ltd.
DOCUMENT TYPE:            Journal
```

LANGUAGE: English

AB 6-(Nitrooxy)hexyl-(2z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate (enoate 1) was investigated as a novel therapy for pain relief. In a recent manufacturing run at the pilot plant scale, the enoate drug substance was found to have a yellowish color not observed previously. An unknown impurity at trace level was detected by high-performance liquid chromatog. (HPLC) anal. and found to be the primary cause for the color of the drug substance. The colored impurity was enriched by preparative HPLC and structurally elucidated by liquid chromatog./tandem mass spectrometry (LC/MS/MS). It was found that the colored impurity was derived from the product of oxidative dimerization of rofecoxib, an impurity present in the enoic acid intermediate. It was further revealed by the photodiode array and LC/MS/MS data that the colored impurity exists in the drug substance as a pair of double-bond isomers with one isomer at majority. These findings were also confirmed by synthesizing the colored impurity through the proposed pathway.

IT 754241-98-0
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(identification of colored impurity in drug substance by preparative HPLC)

RN 754241-98-0 CAPLUS

CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, (αZ)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1315893 CAPLUS

DOCUMENT NUMBER: 144:212486

TITLE: Synthesis of a NO-Releasing Prodrug of Rofecoxib

AUTHOR(S): Engelhardt, F. Conrad; Shi, Yao-Jun; Cowden, Cameron J.; Conlon, David A.; Pipik, Brenda; Zhou, George; McNamara, James M.; Dolling, Ulf-H.

CORPORATE SOURCE: Department of Process Research, Merck Company, Rahway, NJ, 07065-0900, USA

SOURCE: Journal of Organic Chemistry (2006), 71(2), 480-491
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



III

AB A newly developed synthesis of a NO-releasing prodrug of rofecoxib is described. The highly productive process consists of five chemical steps and produces prodrug I in an overall 64% yield from com. available 3-phenyl-2-propyn-1-ol (II). The synthesis is highlighted by the carbometalation reaction of propargyl alc. II to generate the tetrasubstituted olefin core, sulfone acid III. Addnl., two alternate end-game strategies to prepare NO-COXIB I from this intermediate were explored and developed: (1) a convergent synthesis where a bromonitrate side chain is introduced in one step and (2) a two-step sequence that first installs the requisite six-carbon ester side chain followed by chemoselective nitration.

IT 754241-98-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of a NO-releasing prodrug of rofecoxib in five chemical steps from 3-phenyl-2-propyn-1-ol)

RN 754241-98-0 CAPLUS

CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, (αZ)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:963804 CAPLUS

DOCUMENT NUMBER: 143:266677
TITLE: Process for making nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
INVENTOR(S): Shi, Yao-Jun; Engelhardt, F. Conrad; Cowden, Cameron John; Conlon, David A.; Pipik, Brenda
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005192346	A1	20050901	US 2005-66676		20050225
PRIORITY APPLN. INFO.:			US 2004-549126P	P	20040301

OTHER SOURCE(S): CASREACT 143:266677; MARPAT 143:266677
GI



I

AB The invention encompasses a novel process for making prodrugs of cyclooxygenase-2 selective inhibitors that convert in vivo to diaryl-2-(5H)-furanones and also liberate nitric oxide in vivo. As such, the compds. may be co-dosed with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions, effectively reduce the risk of thrombotic cardiovascular events and potentially renal side effects and at the same time reduce the risk of GI ulceration or bleeding. I was prepared starting from 3-phenyl-2-propyn-1-ol and 4-thioanisole magnesium chloride, acetylation, and the intermediate converted to the carboxylic acid, the thio group oxidized to the methylsulfonyl derivative and reaction with 6-bromohexyl nitrate to give I.

IT 754241-98-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)
RN 754241-98-0 CAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, (αZ)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:739958 CAPLUS
DOCUMENT NUMBER: 141:260542
TITLE: Preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as selective cyclooxygenase-2 inhibitors
INVENTOR(S): Berthelette, Carl; Li, Lianhai; Sturino, Claudio; Wang, Zhaoyin
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004176331	A1	20040909	US 2004-790288	20040301
AU 2004240700	A1	20041202	AU 2004-240700	20040301
CA 2517490	AA	20041202	CA 2004-2517490	20040301
WO 2004103955	A1	20041202	WO 2004-CA314	20040301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1601644	A1	20051207	EP 2004-761562	20040301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-452124P P 20030305
WO 2004-CA314 W 20040301

OTHER SOURCE(S): MARPAT 141:260542
GI



I



II

AB Title compds. I [X = (CH2)n; n = 3-6; R1 = SO2Me, SO2NH2, SO2NHCOCF3, etc.; R2, R3 = H, halo, alkoxy, etc.; R4 = CO-alkyl, CO(CH2)mNR5R6; m = 1-4; R5, R6 = H, halo-substituted alkyl] and their pharmaceutically acceptable salts were prepared For example, O-alkylation of AgNO3 by bromide II (Z = Br), e.g., prepared from Rofecoxib in 6-steps, afforded nitrooxyhexyl II (Z = -ONO2). In human blood PGE2 inhibition production assays, nitrooxyhexyl II (Z = -ONO2) exhibited an IC50 value of 0.22 μM. Of note, the "unconverted prodrugs" of compds. I are inactive inhibitors of COX-1 and COX-2 activity. Compds. I are claimed useful for the treatment of cyclooxygenase-2 mediated diseases or conditions.

IT 754241-98-0P 754241-99-1P 754242-00-7P
754242-01-8P 754242-02-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitric oxide releasing prodrugs of diarylfuranones as selective COX-2 inhibitors)

RN 754241-98-0 CAPLUS

CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, (αZ)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 754241-99-1 CAPLUS
CN Glycine, (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenyl-2-butenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 754242-00-7 CAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 5-(nitrooxy)pentyl ester, (αZ)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 754242-01-8 CAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 7-(nitrooxy)heptyl ester, (αZ)-

(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 754242-02-9 CAPLUS
CN Glycine, (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenyl-2-butenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 754242-09-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitric oxide releasing prodrugs of diarylfuranones as selective COX-2 inhibitors)
RN 754242-09-6 CAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-, (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenyl-2-butenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    21.41     188.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.00      -3.00

FILE 'REGISTRY' ENTERED AT 15:39:56 ON 18 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   17 SEP 2006  HIGHEST RN 907180-17-0
DICTIONARY FILE UPDATES:  17 SEP 2006  HIGHEST RN 907180-17-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer
be available.  Please contact CAS Customer Care
(http://www.cas.org/supp.html) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> rofecoxib
L5            1 ROFECOXIB
```

=> d str

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.58	195.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.00

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:41:10 ON 18 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 15:47:23 ON 18 SEP 2006
FILE 'REGISTRY' ENTERED AT 15:47:23 ON 18 SEP 2006
COPYRIGHT (C) 2006 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.58	195.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

```
CA SUBSCRIBER PRICE                                          0.00      -3.00

=> d his

     (FILE 'HOME' ENTERED AT 15:38:13 ON 18 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 15:38:24 ON 18 SEP 2006
L1             STRUCTURE UPLOADED
L2           0 L1
L3           6 L1 FULL

     FILE 'MEDLINE, CAPLUS' ENTERED AT 15:38:53 ON 18 SEP 2006
L4           4 L3

     FILE 'REGISTRY' ENTERED AT 15:39:56 ON 18 SEP 2006
L5           1 ROFECOXIB

=> file medline caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     6.58     195.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -3.00

FILE 'MEDLINE' ENTERED AT 15:47:38 ON 18 SEP 2006

FILE 'CAPLUS' ENTERED AT 15:47:38 ON 18 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> l5
L6        1523 L5

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7         1521 DUP REM L6 (2 DUPLICATES REMOVED)

=> l7 and prodrug
L8           49 L7 AND PRODRUG

=> d ibib abs 1-49

L8   ANSWER 1 OF 49  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2006:740188  CAPLUS
DOCUMENT NUMBER:         145:159849
TITLE:                   Methods and compositions using cyclooxygenase 2
                         (COX-2) inhibitors for the treatment of psychiatric
                         disorders, and combination therapies
INVENTOR(S):             Muller, Norbert
PATENT ASSIGNEE(S):      Germany
SOURCE:                  U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S.
                         Ser. No. 157,969.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  3
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006167074	A1	20060727	US 2005-320757	20051230
US 2003130334	A1	20030710	US 2002-157969	20020531
EP 1627639	A2	20060222	EP 2005-24864	20020531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:

DE 2001-10129328	A	20010619
US 2002-364904P	P	20020314
US 2002-157969	A2	20020531
DE 2001-10129320	A	20010619
EP 2002-738138	A3	20020531

AB A method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia, is described which comprises administering a COX-2 inhibitor or prodrug thereof to a subject. Moreover, a method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia or depressive disorders, is disclosed comprising administering to a subject a COX-2 inhibitor or prodrug thereof in combination with a neuroleptic drug or an antidepressant. Compns. and kits that are suitable for the practice of the method are also described.

L8 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:453900 CAPLUS
DOCUMENT NUMBER: 145:116702
TITLE: Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia
AUTHOR(S): Caturla, Francisco; Amat, Merce; Reinoso, Raquel F.; Cordoba, Monica; Warrellow, Graham
CORPORATE SOURCE: Department of Medicinal Chemistry, Almirall Prodesfarma S.A., Research Center, Barcelona, 08024, Spain
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(12), 3209-3212
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The preparation of the sulfoxide analogs (I) and (II), and their enantiomeric pure forms is discussed as well as their potential to act as prodrugs to the potent and selective sulfone-containing COX-2 inhibitors rofecoxib and etoricoxib. Sulfoxides I and II were shown to be effectively transformed

in vivo into rofecoxib and etoricoxib, resp., after oral administration in rats. In the case of sulfoxide I, both a slightly improved pharmacokinetic profile and a better pharmacol. activity in an arthritis model were seen when compared with rofecoxib.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1315893 CAPLUS
DOCUMENT NUMBER: 144:212486
TITLE: Synthesis of a NO-Releasing Prodrug of Rofecoxib
AUTHOR(S): Engelhardt, F. Conrad; Shi, Yao-Jun; Cowden, Cameron J.; Conlon, David A.; Pipik, Brenda; Zhou, George; McNamara, James M.; Dolling, Ulf-H.
CORPORATE SOURCE: Department of Process Research, Merck Company, Rahway, NJ, 07065-0900, USA
SOURCE: Journal of Organic Chemistry (2006), 71(2), 480-491
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



III

AB A newly developed synthesis of a NO-releasing prodrug of rofecoxib is described. The highly productive process consists of five chemical steps and produces prodrug I in an overall 64% yield from com. available 3-phenyl-2-propyn-1-ol (II). The synthesis is highlighted by the carbometalation reaction of propargyl alc. II to generate the tetrasubstituted olefin core, sulfone acid III. Addnl., two alternate end-game strategies to prepare NO-COXIB I from this intermediate were explored and developed: (1) a convergent synthesis where a bromonitrate side chain is introduced in one step and (2) a two-step sequence that first installs the requisite six-carbon ester side chain followed by chemoselective nitration.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1294044 CAPLUS
DOCUMENT NUMBER: 144:17160
TITLE: Method using camptothecin compounds, pyrimidine derivatives, and antitumor agents for treating abnormal cell growth
INVENTOR(S): Denis, Louis J.; Compton, Linda D.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005272755	A1	20051208	US 2005-145097	20050603
WO 2005117980	A1	20051215	WO 2005-IB1527	20050523

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-577268P P 20040604
AB The invention discloses a method for treating abnormal cell growth in a subject, comprising administering to the subject (a) a compound selected from a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug thereof; (b) a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof; and (c) an antitumor agent selected from antiproliferative agents, kinase inhibitors, angiogenesis inhibitors, growth factor inhibitors, COX-1 inhibitors, COX-2 inhibitors, mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biol. response modifiers, antibodies, cytotoxics, antihormones, antiandrogens and combinations thereof.

L8 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1291841 CAPLUS
DOCUMENT NUMBER: 144:40800
TITLE: Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
INVENTOR(S): Capomacchia, Anthony C.; Garner, Solomon T., Jr.; Beach, J. Warren
PATENT ASSIGNEE(S): The University of Georgia Research Center Inc., USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116086	A2	20051208	WO 2005-US11739	20050407
WO 2005116086	A3	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-560128P P 20040407
OTHER SOURCE(S): MARPAT 144:40800

AB Mutual prodrugs of glucosamine, and derivs. and analogs of glucosamine and an anti-inflammatory agent, compns. thereof, and methods for, e.g., treating disorders and conditions by administration of the compns. are provided. Topical compns. of glucosamine, and derivs. and analogs of glucosamine are also provided.

L8 ANSWER 6 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1155282 CAPLUS
DOCUMENT NUMBER: 143:427372
TITLE: Methods and compositions for preventing or treating periodontal diseases using, for example, Resolvin E1
INVENTOR(S): Van, Dyke Thomas E.; Petasis, Nicos A.; Serhan, Charles N.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005238589	A1	20051027	US 2005-106141	20050414
WO 2005105025	A1	20051110	WO 2005-US12552	20050414

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-562099P P 20040414
OTHER SOURCE(S): MARPAT 143:427372
GI



I

AB Methods and compns. for preventing or treating periodontal diseases, including gingivitis and periodontitis are provided. The compns. comprise a prophylactically or therapeutically effective amount of a compound I (R1,R2, R3 = OR, OX1, SR, SX2, N(R)2, NHX3, NRC(O)R, NRC(O)N(R)2, CO2R, C(O)N(R)2, SO2R, NRSO2, C(O)R, SO2N(R)2; R = C1-6 aliphatic, 3-8 membered saturated, aryl; heterocycle, heteroaryl; X1,X2,X3 = protecting group; R4 = NRC(O)R, NRC(O)N(R), C(O)OR, C(O)N(R)2, SO2R, NRSO2R, C(O)R, or SO2N(R)2), or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier. The composition further includes a COX-2 inhibitor selected from celecoxib, rofecoxib, and valdecoxib. The invention also provides methods for preventing or treating secondary diseases within or beyond the oral cavity that are related to periodontal disease, such as cardiovascular diseases, pregnancy complications, and diabetes. Thus, topical delivery of Resolvin E1 suspended in ethanol (7 μg/mL) every other day for 6 wk prevented both the bone loss and inflammatory changes in rabbits treated either with ligature alone or ligature plus topical Porphyromonas gingivalis (model of periodontal disease).

L8 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:824492 CAPLUS
DOCUMENT NUMBER: 143:222525
TITLE: Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function, preparation thereof, and use with other agents
INVENTOR(S): Nirschl, Alexandra A.; Hamann, Lawrence G.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005182105	A1	20050818	US 2005-48437		20050201
PRIORITY APPLN. INFO.:			US 2004-541780P	P	20040204

OTHER SOURCE(S): MARPAT 143:222525
GI



I

AB A method is provided for treating androgen receptor-associated conditions, such as age-related diseases, e.g. sarcopenia, employing a compound I [R1 = CN, H; X = O, S; R2 = (substituted) alkyl, (substituted) cycloalkyl, etc; R3, R4 = H, (substituted) alkyl, etc.; G = (substituted) aryl, (substituted) heteroaryl], or a pharmaceutically acceptable salt or prodrug ester thereof. Preparation of selected I is described. I may be used in combination with other agents.

L8 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:696865 CAPLUS
DOCUMENT NUMBER: 143:193802
TITLE: Preparation of nitric oxide releasing prodrugs of diaryl-2(5H)-furanones as cyclooxygenase-2 inhibitors
INVENTOR(S): Berthelette, Carl; Li, Lianhai; Beaulieu, Christian; Wang, Zhaoyin; Sturino, Claudio F.
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070874	A1	20050804	WO 2005-CA84	20050125

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-540101P P 20040127
OTHER SOURCE(S): MARPAT 143:193802
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [n = 1-6; R1 = SO2CH3, SO2NH2; R2-3 = H, halo, alkoxy, etc.; R4 = alkyl, Ph, etc.] are prepared For instance, II is prepared in several steps from 4-(4-(methanesulfonyl)phenyl)-3-phenyl-5H-furan-2-one and hex-5-en-1-ol. I are nitric oxide-releasing prodrugs of

diaryl-2(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases [no data]. I may also be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:460617 CAPLUS
DOCUMENT NUMBER: 144:186912
TITLE: Examination of 209 drugs for inhibition of cytochrome P450 2C8
AUTHOR(S): Walsky, Robert L.; Gaman, Emily A.; Obach, R. Scott
CORPORATE SOURCE: Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Global Research and Development, Groton/New London Laboratories, Groton, CT, USA
SOURCE: Journal of Clinical Pharmacology (2005), 45(1), 68-78
CODEN: JCPCBR; ISSN: 0091-2700
PUBLISHER: Sage Publications
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Cytochrome P 450 2C8 is involved in the metabolism of drugs such as paclitaxel, repaglinide, rosiglitazone, and cerivastatin, among others. An in vitro assessment of 209 frequently prescribed drugs and related xenobiotics was carried out to examine their potential to inhibit CYP2C8. A validated sensitive, moderate-throughput high-performance liquid chromatog./tandem mass spectrometry(HPLC/MS/MS) assay was used to detect N-desethylamodiaquine, the CYP2C8-derived major metabolite of amodiaquine metabolism, using heterologously expressed recombinant CYP2C8 (rhCYP2C8) and pooled human liver microsomes. The 209 drugs were first tested at 30 μM for their ability to inhibit rhCYP2C8. Forty-eight compds. exhibited greater than 50% inhibition and were further evaluated for measurement of IC50. The six most potent inhibitors (IC50 <1 μM) from this set were measured for IC50 in pooled human liver microsomes, and the most potent inhibitor identified was the leukotriene receptor antagonist, montelukast (IC50 = 19.6 nM). Inhibitors of CYP2C8 were identified from a wide variety of therapeutic classes, with no single class predominating. Other potent inhibitors included candesartan cilexetil (cyclohexylcarbonate ester prodrug of candesartan), zafirlukast, clotrimazole, felodipine, and mometasone furoate. Seventeen moderate inhibitors of rhCYP2C8 (1 < IC50 < 10 μM) included salmeterol, raloxifene, fenofibrate, ritonavir, levothyroxine, tamoxifen, loratadine, quercetin, oxybutynin, medroxyprogesterone, simvastatin, ketoconazole, ethinyl estradiol, spironolactone, lovastatin, nifedipine, and irbesartan. These in vitro data were used along with clin. pharmacokinetic information in predicting potential drug-drug interactions that could occur by inhibition of CYP2C8. Although almost all drugs tested are not expected to cause drug interactions via inhibition of CYP2C8, montelukast was identified as being of concern as a potential inhibitor of clin. relevance. These findings are discussed in context to potential drug interactions that could be observed between these agents and drugs for which CYP2C8 is involved in metabolism and warrant investigation of the possibility of clin. drug interactions mediated by inhibition of this enzyme.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:451140 CAPLUS
DOCUMENT NUMBER: 142:476264

TITLE: Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system-mediated disorders
INVENTOR(S): Taylor, Duncan P.; Stephenson, Diane T.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company LLC, USA
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046615	A2	20050526	WO 2004-US37882	20041112
WO 2005046615	A3	20060622		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2545731	AA	20050526	CA 2004-2545731	20041112
US 2005148589	A1	20050707	US 2004-987876	20041112
EP 1684784	A2	20060802	EP 2004-801034	20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				

PRIORITY APPLN. INFO.: US 2003-519471P P 20031112
WO 2004-US37882 W 20041112
OTHER SOURCE(S): MARPAT 142:476264

AB The invention provides compns. and methods for the treatment of central nervous system-mediated disorders. More particularly, the invention provides a combination therapy for the treatment of a central nervous system-mediated disorder which comprises the administration of a neurotrophic factor-modulating agent in combination with a cyclooxygenase-2 selective inhibitor.

L8 ANSWER 11 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:409223 CAPLUS
DOCUMENT NUMBER: 142:441891
TITLE: Method and compositions for the treatment and prevention of pain and inflammation with cyclooxygenase-2 inhibitors and polyunsaturated fatty acids
INVENTOR(S): Pulaski, Steven P.; Kundel, Susan
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of U.S. Ser. No. 215,539.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101563	A1	20050512	US 2004-783160	20040219
US 2003114416	A1	20030619	US 2002-215539	20020809
CN 1575182	A	20050202	CN 2002-820121	20020813
ZA 2004001163	A	20050622	ZA 2004-1163	20040212
PRIORITY APPLN. INFO.:			US 2001-312211P	P 20010814
			US 2002-215539	A2 20020809

AB A method of preventing or treating pain or inflammation in a subject is provided by administering to the subject a Cox-2 inhibitor and a polyunsatd. fatty acid, or a prodrug thereof, wherein the amount of a Cox-2 inhibitor and polyunsatd. fatty acid or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount Glucosamine and/or chondroitin can optionally be present. Therapeutic compns. that contain the combination of Cox-2 inhibitor and polyunsatd. fatty acid and, optionally, the glucosamine and/or chondroitin, are disclosed, as are pharmaceutical compns.

L8 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:259661 CAPLUS
DOCUMENT NUMBER: 142:336520
TITLE: Preparation, pharmaceutical compositions, and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a cyclooxgenase-2 inhibitor
INVENTOR(S): Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065130	A1	20050324	US 2004-943561	20040916
WO 2005027918	A1	20050331	WO 2004-IB2913	20040906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-504003P	P 20030919

GI



I

AB The invention relates to pharmaceutical compns., and methods of treatment comprising administering to a patient in need of a combination of a 2-alkylidene-19-nor-vitamin D derivative and a cyclooxgenase-2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need of 2-methylene-19-nor-20(S)-10,25-dihydroxyvitamin D3 and a cyclooxgenase-2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof. Thus, 1α,25-dihydroxy-2-methylene-19-norvitamin D3 (I) was prepared in 11 steps from (-)-quinic acid. and (20S)-1α,25-dihydroxy-2-methylene-19-norvitamine D3 was prepared from (20S)-25-[(triethylsilyl)oxy]-des-A,B-cholestan-8-one in 4 steps.

L8 ANSWER 13 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:216610 CAPLUS
DOCUMENT NUMBER: 142:291412
TITLE: Compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic-mediated central nervous system disorders or injury
INVENTOR(S): Arneric, Stephen P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020910	A2	20050310	WO 2004-US27600	20040826
WO 2005020910	A3	20050609		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005085479 A1 20050421 US 2004-926751 20040826
PRIORITY APPLN. INFO.: US 2003-498148P P 20030827
OTHER SOURCE(S): MARPAT 142:291412

AB The invention provides compns. and methods for the treatment of ischemic-mediated central nervous system disorder or injury. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic-mediated disorder or injury comprising the administration to a subject of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist or a pharmaceutically acceptable salt or a prodrug thereof.

L8 ANSWER 14 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:177827 CAPLUS
DOCUMENT NUMBER: 142:254634
TITLE: Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage
INVENTOR(S): Stephenson, Diane T.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018541	A2	20050303	WO 2004-US22059	20040708
WO 2005018541	A3	20060309		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005080084 A1 20050414 US 2004-887112 20040708
PRIORITY APPLN. INFO.: US 2003-486549P P 20030711
OTHER SOURCE(S): MARPAT 142:254634

AB The invention provides compns. and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a serotonin-modulating agent in combination with a cyclooxygenase-2 selective inhibitor.

L8 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:99157 CAPLUS
DOCUMENT NUMBER: 142:170033
TITLE: Methods and compositions for the treatment or

prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
INVENTOR(S): Maziasz, Timothy
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 172 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005026902	A1	20050203	US 2004-769485		20040130
PRIORITY APPLN. INFO.:			US 2003-443910P	P	20030131

OTHER SOURCE(S): MARPAT 142:170033
AB The present invention provides compns. and methods for the treatment of human immunodeficiency virus (HIV) infection as well as HIV associated diseases and related disorders. More particularly, the invention provides a combination therapy for the treatment of HIV infection as well as HIV associated diseases and related disorders comprising the administration to a subject of an anti-human immunodeficiency virus agent in combination with a cyclooxygenase-2 selective inhibitor or an isomer or a pharmaceutically acceptable salt, ester, or prodrug thereof.

L8 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:76247 CAPLUS
DOCUMENT NUMBER: 142:148812
TITLE: Compositions of a cyclooxygenase-2 selective inhibitor and a non-NMDA glutamate modulator for the treatment of central nervous system damage
INVENTOR(S): Stephenson, Diane T.; Taylor, Duncan P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005007106	A2	20050127	WO 2004-US22189		20040708
WO 2005007106	A3	20060608			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005101597	A1	20050512	US 2004-887035		20040708
PRIORITY APPLN. INFO.:			US 2003-486654P	P	20030710

OTHER SOURCE(S): MARPAT 142:148812
AB The invention provides compns. and methods for the treatment of central

nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a non-NMDA glutamate modulator in combination with a cyclooxygenase-2 selective inhibitor.

L8 ANSWER 17 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1020415 CAPLUS
DOCUMENT NUMBER: 142:190038
TITLE: Selective cyclooxygenase-2 inhibitors: similarities and differences
AUTHOR(S): Brune, K.; Hinz, B.
CORPORATE SOURCE: Department of Experimental and Clinical Pharmacology and Toxicology, Emil Fischer Center, Friedrich Alexander University, Erlangen, Germany
SOURCE: Scandinavian Journal of Rheumatology (2004), 33(1), 1-6
CODEN: SJRHAT; ISSN: 0300-9742
PUBLISHER: Taylor & Francis
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. The enzyme cyclooxygenase (COX) was shown to exist as two distinct isoforms about a decade ago. COX-1 is constitutively expressed as a 'housekeeping' enzyme in nearly all tissues, and mediates physiol. responses (e.g. cytoprotection of the stomach, and platelet aggregation). On the other hand, COX-2, expressed by cells involved in inflammation (e.g. macrophages, monocytes, synoviocytes), has emerged as the isoform that is primarily responsible for the synthesis of prostanoids involved in acute and chronic inflammatory states. Consequently, the hypothesis that selective inhibition of COX-2 might have therapeutic actions similar to those of non-steroidal anti-inflammatory drugs, but without causing gastrointestinal side effects, was the rationale for the development of selective inhibitors of the COX-2 isoenzyme. Selective COX-2 inhibitors currently used in the clinic are the sulfonamides celecoxib and valdecoxib (parecoxib is a prodrug of valdecoxib), as well as the methylsulfones rofecoxib and etoricoxib. Furthermore, the phenylacetic acid derivative lumiracoxib has gained permission recently to be marketed in Europe. This review discusses the clin. relevant similarities and differences of these substances, with particular emphasis on their diverse pharmacokinetic characteristics.
REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:754407 CAPLUS
DOCUMENT NUMBER: 141:271579
TITLE: Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
INVENTOR(S): Briggs, Michael; Ornberg, Richard; Hauser, Scott; Koki, Alane
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004078113	A2	20040916	WO 2004-US3219	20040205
WO 2004078113	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004204472	A1	20041014	US 2004-773019	20040205
PRIORITY APPLN. INFO.:			US 2003-451885P	P 20030304

AB A method for preventing or treating obesity and obesity-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a conventional weight-loss agent. Also described are therapeutic compns. comprising a Cox-2 inhibitor and a conventional weight-loss agent. Pharmaceutical compns. and kits for implementing the present method are also described.

L8 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2004:739958 CAPLUS
DOCUMENT NUMBER:	141:260542
TITLE:	Preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as selective cyclooxygenase-2 inhibitors
INVENTOR(S):	Berthelette, Carl; Li, Lianhai; Sturino, Claudio; Wang, Zhaoyin
PATENT ASSIGNEE(S):	Can.
SOURCE:	U.S. Pat. Appl. Publ., 19 pp. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004176331	A1	20040909	US 2004-790288	20040301
AU 2004240700	A1	20041202	AU 2004-240700	20040301
CA 2517490	AA	20041202	CA 2004-2517490	20040301
WO 2004103955	A1	20041202	WO 2004-CA314	20040301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1601644	A1	20051207	EP 2004-761562	20040301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:	US 2003-452124P	P 20030305
	WO 2004-CA314	W 20040301
OTHER SOURCE(S):	MARPAT 141:260542	

GI



I



II

AB Title compds. I [X = (CH2)n; n = 3-6; R1 = SO2Me, SO2NH2, SO2NHCOCF3, etc.; R2, R3 = H, halo, alkoxy, etc.; R4 = CO-alkyl, CO(CH2)mNR5R6; m = 1-4; R5, R6 = H, halo-substituted alkyl] and their pharmaceutically acceptable salts were prepared For example, O-alkylation of AgNO3 by bromide II (Z = Br), e.g., prepared from Rofecoxib in 6-steps, afforded nitrooxyhexyl II (Z = -ONO2). In human blood PGE2 inhibition production assays, nitrooxyhexyl II (Z = -ONO2) exhibited an IC50 value of 0.22 μM. Of note, the "unconverted prodrugs" of compds. I are inactive inhibitors of COX-1 and COX-2 activity. Compds. I are claimed useful for the treatment of cyclooxygenase-2 mediated diseases or conditions.

L8 ANSWER 20 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:589414 CAPLUS
DOCUMENT NUMBER: 141:134107
TITLE: A method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
INVENTOR(S): Arneric, Stephen P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060366	A1	20040722	WO 2003-US38751	20031206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004235925	A1	20041125	US 2003-727717		20031204
CA 2508884	AA	20040722	CA 2003-2508884		20031206
AU 2003294590	A1	20040729	AU 2003-294590		20031206
BR 2003017361	A	20051116	BR 2003-17361		20031206
PRIORITY APPLN. INFO.:			US 2002-433790P	P	20021217
			WO 2003-US38751	W	20031206

OTHER SOURCE(S): MARPAT 141:134107

AB A method of treating, preventing, or inhibiting a CNS disorder and/or pain and inflammation or an inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of duloxetine, venlafaxine or atomoxetine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a CNS disorder, pain and inflammation, or inflammation-associated disorder suppressing treatment, prevention, or inhibition effective amount of the composition Compns. and pharmaceutical compns. that contain duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor are also disclosed.

L8 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:589409 CAPLUS
DOCUMENT NUMBER: 141:117197
TITLE: Compositions and a method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor
INVENTOR(S): Arneric, Stephen P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 192 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060361	A2	20040722	WO 2003-US38770	20031205
WO 2004060361	A3	20040902		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004204411	A1	20041014	US 2003-727918		20031204
CA 2510584	AA	20040722	CA 2003-2510584		20031205
AU 2003303625	A1	20040729	AU 2003-303625		20031205
EP 1575594	A2	20050921	EP 2003-808444		20031205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003017511	A	20051116	BR 2003-17511		20031205
JP 2006513237	T2	20060420	JP 2004-565231		20031205
PRIORITY APPLN. INFO.:			US 2002-433780P	P	20021217
			WO 2003-US38770	W	20031205

OTHER SOURCE(S): MARPAT 141:117197

AB A method of treating, preventing, or inhibiting a CNS disorder and/or pain and inflammation, or an inflammation-associated disorder in a subject in need of such treatment, prevention, or inhibition provides administering to the subject a combination of reboxetine and a cyclooxygenase-2 selective inhibitor or prodrug thereof. Pharmaceutical compns. containing reboxetine and a cyclooxygenase-2 selective inhibitor are also disclosed. For example, a combination of reboxetine and celebrex provided an effective anti-inflammatory activity in a rat carrageenan foot pad edema test, an effective analgesic activity in a rat carrageenan-induced analgesia test, and it was an efficacious treatment for collagen-induced arthritis in mice.

L8 ANSWER 22 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:412933 CAPLUS
DOCUMENT NUMBER: 140:423574
TITLE: Preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
INVENTOR(S): Young, Robert N.; Wang, Zhaoyin
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004041803	A1	20040521	WO 2003-CA1691		20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003283096	A1	20040607	AU 2003-283096		20031103
PRIORITY APPLN. INFO.:			US 2002-423866P	P	20021105
			WO 2003-CA1691	W	20031103

OTHER SOURCE(S): MARPAT 140:423574
GI



I

AB The title compds. I [R1 = SO2Me, etc.; R2, R3 = H, halo, etc.; R4 = NOm, etc.; m = 1 or 2] are prepared The above compds. may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases while simultaneously reducing the risk of thrombotic cardiovascular events.

L8 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:392439 CAPLUS
DOCUMENT NUMBER: 140:400095
TITLE: Stereoisomers of p-hydroxy-milnacipran, and therapeutic use
INVENTOR(S): Rariy, Roman V.; Heffernan, Michael; Buchwald, Stephen L.; Swager, Timothy M.
PATENT ASSIGNEE(S): Collegium Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039320	A2	20040513	WO 2003-US33681	20031022
WO 2004039320	A3	20040624		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2503381	AA	20040513	CA 2003-2503381	20031022
AU 2003284342	A1	20040525	AU 2003-284342	20031022
US 2004142904	A1	20040722	US 2003-691465	20031022
US 7038085	B2	20060502		
EP 1578719	A2	20050928	EP 2003-776524	20031022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503920	T2	20060202	JP 2005-501895	20031022

PRIORITY APPLN. INFO.:
US 2002-421640P P 20021025
US 2002-423062P P 20021101

US 2003-445142P P 20030205
WO 2003-US33681 W 20031022

OTHER SOURCE(S): MARPAT 140:400095

AB The invention relates generally to the enantiomers of p-hydroxymilnacipran or congeners thereof. Biol. assays revealed that racemic p-hydroxymilnacipran is approx. equipotent in inhibiting serotonin and norepinephrine uptake (IC50 = 28.6 nM for norepinephrine, IC50 = 21.7 nM for serotonin). Interestingly, (+)-p-hydroxymilnacipran is a more potent inhibitor of norepinephrine uptake than serotonin uptake (IC50 = 10.3 nM for norepinephrine, IC50 = 22 nM for serotonin). In contrast, (-)-p-hydroxymilnacipran is a more potent inhibitor of serotonin uptake compared to norepinephrine uptake (IC50 = 88.5 nM for norepinephrine, IC50 = 40.3 nM for serotonin). The invention also relates to salts and prodrug forms of the above compds. In certain embodiments, the compds. of the invention and a pharmaceutically acceptable excipient are combined to prepare a formulation for administration to a patient. Finally,the invention relates to methods of treating mammals suffering from various afflictions, e.g., depression, chronic pain, or fibromyalgia, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of the invention. Compound preparation is included.

L8 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:101124 CAPLUS
DOCUMENT NUMBER: 140:163574
TITLE: Preparation of nitric oxide releasing diaryl-2-(5H)-furanone prodrugs as selective cyclooxygenase-2 inhibitors for treatment inflammatory diseases
INVENTOR(S): Berthelette, Carl; Lachance, Nicholas; Li, Lianhai; Sturino, Claudio; Wang, Zhaoyin; Young, Robert N.; Dufresne, Claude
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011421	A1	20040205	WO 2003-CA1115	20030724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493082	AA	20040205	CA 2003-2493082	20030724
AU 2003252515	A1	20040216	AU 2003-252515	20030724
EP 1527045	A1	20050504	EP 2003-771010	20030724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005261245	A1	20051124	US 2005-521075	20050112

PRIORITY APPLN. INFO.: US 2002-398683P P 20020726

US 2002-435341P P 20021220
WO 2003-CA1115 W 20030724

OTHER SOURCE(S): MARPAT 140:163574
GI



I

AB Title compds. I [R1 = S(O)2CH3, S(O)2NH2, S(O)2NHC(=O)CF3, etc.; R2, R3 = H, halo, alkoxy, etc.; R4 = H, (un)substituted alkyl, e.g., halo, Ph, naphthyl, etc.; R5 = NOx, C(=O)-E-alkyl-W-NOx, C(=O)-E-alkyl-Ar-alkyl-W-NOx; x = 1, 2; E = bond, O, S, etc.; W = O, S, C[CO2Rb]2; Ar = (un)substituted Ph, naphthyl, HET3; HET3 = benzimidazolyl, benzofuranyl, benzopyrazolyl, etc.; Rb = (un)substituted alkyl, Ph, naphthyl, etc.] and their pharmaceutically acceptable salts were prepared For example, allylic bromination of Me (2E)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate, e.g., prepared from 1-(4-methanesulfonylphenyl)ethanone in 2 steps, followed by O-alkylation of AgNO3 afforded nitrate ester I [R1 = 4-S(O)2CH3; R2, R3 = H; R4 = CH3; R5 = NO2] in 23% overall yield. In human whole blood LPS induced PGE2 and TXB2 production assays, compds. I have a COX-2 potency and COX-2/COX-1 selectivity comparable to rofecoxib. In paw edema assays in rat, compound I [R1 = 4-S(O)2CH3; R2, R3 = H; R4 = CH3; R5 = CO2(CH2)4ONO2] exhibited 42-79% inhibition of pain at 1-30 mg/kg dosage. Of note, compds. I are prodrugs of rofecoxib analogs and are claimed useful for the treatment of chronic COX-2 mediated diseases, while reducing the risk of thrombotic cardiovascular events. Compds. I are useful for treatments of osteoarthritis, rheumatoid arthritis, and chronic pain.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:20448 CAPLUS
DOCUMENT NUMBER: 140:87676
TITLE: Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
INVENTOR(S): Tseng, Ben; Sirisoma, Nilantha Sudath; Cai, Sui Xiong; Zhang, Han-Zhong; Kasibhatla, Shailaja; Ollis, Kristin P.; Drewe, John A.
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002428	A2	20040108	WO 2003-US20668	20030701
WO 2004002428	A3	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491698	AA	20040108	CA 2003-2491698	20030701
AU 2003267977	A1	20040119	AU 2003-267977	20030701
US 2004082066	A1	20040429	US 2003-609670	20030701
EP 1562598	A2	20050817	EP 2003-748924	20030701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1738620	A	20060222	CN 2003-815628	20030701
JP 2006507227	T2	20060302	JP 2004-518157	20030701
PRIORITY APPLN. INFO.:			US 2002-392358P P	20020701
			US 2002-413649P P	20020926
			WO 2003-US20668 W	20030701

OTHER SOURCE(S): MARPAT 140:87676

AB The invention is directed to derivs. of gambogic acid and analogs thereof. Exemplary gambogic acid derivs. of the present invention include, among others, derivs. substituted in the C10 and C28 positions of gambogic acid. The present invention also relates to the discovery that certain preferred compds. of the invention are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs.

L8 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:2830 CAPLUS
DOCUMENT NUMBER: 140:59410
TITLE: Preparation of nitrooxy derivatives of cyclooxygenase-2 inhibitors
INVENTOR(S): Del Soldato, Piero; Santus, Giancarlo
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000781	A2	20031231	WO 2003-EP6502	20030620
WO 2004000781	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				

PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2491209	AA	20031231	CA 2003-2491209	20030620
AU 2003245972	A1	20040106	AU 2003-245972	20030620
EP 1517889	A2	20050330	EP 2003-738069	20030620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1662490	A	20050831	CN 2003-814682	20030620
JP 2005530836	T2	20051013	JP 2004-514803	20030620
ZA 2004010060	A	20051020	ZA 2004-10060	20041213
NO 2005000346	A	20050228	NO 2005-346	20050121
US 2006106082	A1	20060518	US 2005-516938	20050913
PRIORITY APPLN. INFO.:			IT 2002-MI1391 A	20020625
			WO 2003-EP6502 W	20030620

OTHER SOURCE(S): MARPAT 140:59410

AB Disclosed are new compds. able to release COX-2 inhibitors and NO (no data) having formula M-T-YA-NO2 [wherein M-T = the residue of a COX-2 selective inhibitor (T = SO2NH, SO2NR, CO, O, S, NH, N(SO2R); R = C1-10 alkyl; the COX-2 selective inhibitor, M-TH or M-TOH, has to meet test 2 mentioned in the description); YA = -(B)b0-(C)c0- [b0, c0 = 0,1, with the proviso that b0 and c0 cannot be simultaneously 0; B = TB-X2-TB1; TB = CO, X; X = O, S, NH, NR, R (defined above); TB = CO when T = SO2NH, SO2NR-O, S, NH, or N(SO2R), TB = X when T = CO; TB1 = CO or X (defined above); X2 = a divalent radical selected from the following compds. Q or Q1, etc. (n1, n2 = 0, 1; R2, R3 = H, Me; Y1 = CH2CH2, CH:CH(CH2)n2; n2 = 0, 1)]] for the treatment and/or prophylaxis of inflammatory disorders, pain, fever, cardiovascular disease, gastrointestinal disorders, tumors, Alzheimer's disease, or disorders resulting from elevated levels of COX-2. These compds. including 5-niroxypentanoc acid, 4-nitrooxybutyric acid, and 4-nitrooxybutyramide, 2-nitroxymethylbenzoic acid ester derivs. mitigate or remove the known side-effects of COX-2 inhibitors. The inflammatory disorders are selected from the group consisting of, but not limited to, arthritis, rheumatoid arthritis, osteoarthritis, allergic rhinitis, sinusitis, chronic obstructive pulmonary diseases, dermatitis, psoriasis, cystic fibrosis, multiple sclerosis, vasculitis and organ transplant rejection. The cardiovascular diseases are selected from the group consisting of, but not limited to, atherosclerosis, restenosis, coronary artery disease, angina, diabetes mellitus, diabetic nephropathy, diabetic retinopathy, stroke and myocardial infarct. The gastrointestinal disorders are selected from the group consisting of, but not limited to, inflammatory intestinal disorders, Crohn's disease, gastritis, ulcerative colitis, peptic ulcer, hemorrhagic ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison's syndrome, bacterial infections, hypersecretory states associated with systemic mastocytosis or basophilic leukemia and hyperhystaminemia. The disorders resulting from elevated levels of COX-2 are selected from the group consisting of, but not limited to, angiogenesis, arthritis, asthma, bronchitis, menstrual cramps, tendonitis, bursitis, neoplasia, ophthalmic diseases, pulmonary inflammations, central nervous system disorders, allergic rhinitis, atherosclerosis, endothelial disorders, organs and tissues preservation, inhibition and/or prevention of platelets aggregation. Thus, N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1-inden-5-yl]-N-[4-(chloro)butyroyloxymethyl]methanesulfonamide. A solution of chloromethyl (4-chloro)butyrate (1 g, 5.40 mmol) in anhydrous THF (5 mL) was slowly added dropwise in a suspension of N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1-inden-5-yl]methanesulfonamide sodium salt (2.04 g, 5.40 mmol) in

anhydrous THF (25 mL) and stirred at room temperature overnight to give, after workup and silica gel chromatog., N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1-inden-5-yl]-N-[4-(chloro)butyroyloxymethyl]methanesulfonamide (I). A solution of I (1 g, 1.98 mmol) in MeCN (20 mL) was added with AgNO3 (0.67 g, 3.96 mmol), heated at 80° for 15 h in the absence of light, filtered to remove the silver salt, evaporated under vacuum, and purified by chromatog. on a silica gel column to give with n-hexane/ethyl acetate 8/2 as eluent to give 503 mg N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1-inden-5-yl]-N-[4-(nitrooxy)butyroyloxymethyl]methanesulfonamide.

L8 ANSWER 27 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:971878 CAPLUS
DOCUMENT NUMBER: 140:13075
TITLE: Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX 2) inhibitor(s)
INVENTOR(S): Isakson, Peter C.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003101441	A1	20031211	WO 2003-US14548		20030528
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2004063752	A1	20040401	US 2003-444072		20030523
CA 2487923	AA	20031211	CA 2003-2487923		20030528
AU 2003232096	A1	20031219	AU 2003-232096		20030528
BR 2003011518	A	20050222	BR 2003-11518		20030528
EP 1509217	A1	20050302	EP 2003-756170		20030528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1658853	A	20050824	CN 2003-812637		20030528
JP 2005531592	T2	20051020	JP 2004-508799		20030528
PRIORITY APPLN. INFO.:			US 2002-384139P	P	20020531
			US 2003-444072	A	20030523
			WO 2003-US14548	W	20030528

OTHER SOURCE(S): MARPAT 140:13075
AB A method of treating, preventing, or inhibiting amyotrophic lateral sclerosis (ALS), in a subject in need of such treatment, inhibition or prevention. The method comprises administering to a subject one or more cyclooxygenase-2 selective inhibitor(s), or isomer(s), or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, wherein the amount of the cyclooxygenase-2 selective inhibitor(s), isomer(s), ester(s), salt(s) or prodrug(s) thereof constitutes an ALS treatment, inhibition or prevention effective amount of the COX 2 inhibitor(s).
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:971836 CAPLUS
DOCUMENT NUMBER: 140:23256
TITLE: Combination therapy for treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX 2) inhibitor(s) and a second drug
INVENTOR(S): Isakson, Peter C.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 358 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003101380	A2	20031211	WO 2003-US14547		20030528
WO 2003101380	A3	20041111			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2004063751	A1	20040401	US 2003-444071		20030523
CA 2487885	AA	20031211	CA 2003-2487885		20030528
AU 2003241400	A1	20031219	AU 2003-241400		20030528
BR 2003011524	A	20050510	BR 2003-11524		20030528
EP 1539169	A2	20050615	EP 2003-731134		20030528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005534642	T2	20051117	JP 2004-508738		20030528
PRIORITY APPLN. INFO.:			US 2002-384104P	P	20020531
			US 2003-444071	A	20030523
			WO 2003-US14547	W	20030528

OTHER SOURCE(S): MARPAT 140:23256
AB A method of treating, preventing, or inhibiting ALS, in a subject in need of such treatment, inhibition or prevention. The method comprises administering to a subject one or more cyclooxygenase-2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the cyclooxygenase-2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes an ALS treatment, inhibition or prevention effective amount

L8 ANSWER 29 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:855795 CAPLUS
DOCUMENT NUMBER: 139:345939
TITLE: Monotherapy for the treatment of Parkinson's disease with cyclooxygenase 2 (COX2) inhibitor(s)
INVENTOR(S): Stephenson, Diane T.; Isakson, Peter C.; Maziasz,

Timothy J.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088959	A2	20031030	WO 2003-US11517	20030414
WO 2003088959	A3	20031231		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2482510	AA	20031030	CA 2003-2482510	20030414
AU 2003226379	A1	20031103	AU 2003-226379	20030414
US 2004006100	A1	20040108	US 2003-412970	20030414
BR 2003009337	A	20050215	BR 2003-9337	20030414
EP 1505962	A2	20050216	EP 2003-746984	20030414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005532293	T2	20051027	JP 2003-585711	20030414

PRIORITY APPLN. INFO.: US 2002-373317P P 20020418
WO 2003-US11517 W 20030414

OTHER SOURCE(S): MARPAT 139:345939

AB The invention provides a method for treating, preventing, or inhibiting Parkinson's disease (PD), in a subject in need of such treatment, inhibition or prevention. The method comprises treating the subject with one or more COX2 selective inhibitor(s), ester(s), salt(s) or prodrug(s) thereof, wherein the amount of the cyclooxygenase-2 selective inhibitor(s), ester(s), salt(s) or prodrug(s) thereof constitutes a PD treatment-, inhibition- or prevention-effective amount of the COX2 inhibitor(s).

L8 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:855794 CAPLUS
DOCUMENT NUMBER: 139:345938
TITLE: Combination therapy including cyclooxygenase 2 (COX2) inhibitor(s) for the treatment of Parkinson's disease
INVENTOR(S): Stephenson, Diane T.; Isakson, Peter C.; Maziasz, Timothy J.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003088958	A2	20031030	WO 2003-US11269		20030414
WO 2003088958	A3	20040819			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2481934	AA	20031030	CA 2003-2481934		20030414
AU 2003223579	A1	20031103	AU 2003-223579		20030414
US 2004034083	A1	20040219	US 2003-413348		20030414
EP 1494664	A2	20050112	EP 2003-719717		20030414

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003009259	A	20050209	BR 2003-9259		20030414
JP 2005528403	T2	20050922	JP 2003-585710		20030414
PRIORITY APPLN. INFO.:			US 2002-373311P	P	20020418
			WO 2003-US11269	W	20030414

OTHER SOURCE(S): MARPAT 139:345938

AB The invention discloses a method for treating, preventing, or inhibiting Parkinson's disease (PD) in a subject in need of such treatment, inhibition, or prevention. The method comprises treating the subject with one or more COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes a PD treatment-, inhibition- or prevention-effective amount

L8 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:656204 CAPLUS
DOCUMENT NUMBER: 139:191422
TITLE: Combinations of a cyclooxygenase-2 selective inhibitor and a TNF-α antagonist and therapeutic uses therefor
INVENTOR(S): Bennett, Dennis A.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 39 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003157061	A1	20030821	US 2002-310454		20021205
PRIORITY APPLN. INFO.:			US 2001-337802P	P	20011205

AB A method for the prevention, treatment, or inhibition of pain, inflammation, or inflammation-related disorder and for the prevention, treatment, or inhibition of a cardiovascular disease or disorder in a subject that is in need of such prevention, treatment or inhibition, involves the administration to the subject of a cyclooxygenase-2 selective inhibitor or prodrug thereof and a TNF-α antagonist. A method can also involve the treatment, prevention, or inhibition of cancer

in a subject in need of such treatment, prevention, or inhibition, by administering to the subject a cyclooxygenase-2 selective inhibitor or prodrug thereof and a TNF-α antagonist which is selected from the group consisting of a compound that affects the synthesis of TNF-α, a compound that inhibits the binding of TNF-α with a receptor specific for TNF-α, and a compound that interferes with intracellular signaling triggered by TNF-α binding with a receptor. Compns., pharmaceutical compns. and kits that can be used with the methods are also described.

L8 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:633408 CAPLUS
DOCUMENT NUMBER: 139:159977
TITLE: Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient, and compositions thereof
INVENTOR(S): MacMillan, Stephen P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003065988	A2	20030814	WO 2003-US3221		20030204
WO 2003065988	A3	20040219			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2474016	AA	20030814	CA 2003-2474016		20030204
AU 2003208967	A1	20030902	AU 2003-208967		20030204
US 2004029864	A1	20040212	US 2003-357747		20030204
EP 1471872	A2	20041103	EP 2003-707692		20030204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003007755	A	20041207	BR 2003-7755		20030204
JP 2005519923	T2	20050707	JP 2003-565414		20030204
PRIORITY APPLN. INFO.:			US 2002-354135P	P	20020204
			WO 2003-US3221	W	20030204

AB A method for the treatment, prevention and amelioration of colds and/or cough in a subject in need of such treatment, prevention and amelioration, comprises administering to the subject a cyclooxygenase-2 selective inhibitor (e.g. celecoxib; preparation given), or prodrug thereof, and one or more colds and cough active ingredient. Compns., pharmaceutical compns. and kits for practicing the method are also disclosed.

L8 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:570770 CAPLUS
DOCUMENT NUMBER: 139:111710

TITLE: Combinations of peroxisome proliferator-activated receptor-α agonists and cyclooxygenase-2 selective inhibitors, and therapeutic uses therefor
INVENTOR(S): Obukowicz, Mark G.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003059294	A2	20030724	WO 2003-US956		20030114
WO 2003059294	A3	20050714			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2003212138	A1	20031113	US 2003-341217		20030113
CA 2472168	AA	20030724	CA 2003-2472168		20030114
AU 2003207535	A1	20030730	AU 2003-207535		20030114
AU 2003207535	A2	20030730			
JP 2005525313	T2	20050825	JP 2003-559459		20030114
EP 1569640	A2	20050907	EP 2003-705746		20030114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1771034	A	20060510	CN 2003-805942		20030114
PRIORITY APPLN. INFO.:			US 2002-348297P	P	20020114
			US 2003-341217	A	20030113
			WO 2003-US956	W	20030114

OTHER SOURCE(S): MARPAT 139:111710

AB Methods for the treatment, prevention, or inhibition of pain, inflammation, or an inflammation-related disorder, and for the treatment or inhibition of a cardiovascular disease or disorder, and for the treatment or inhibition of cancer, and for the treatment of Alzheimer's disease in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor-α agonist and a cyclooxygenase-2 selective inhibitor (e.g. celecoxib; preparation described), or prodrug thereof. Compns., pharmaceutical compns., and kits for effecting the particular methods are also described.

L8 ANSWER 34 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:570750 CAPLUS
DOCUMENT NUMBER: 139:111706
TITLE: peroxisome proliferator-activated receptor-α agonist- and cyclooxygenase-2 selective inhibitor-containing compositions, and methods of treatment using them
INVENTOR(S): Needleman, Philip
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 157 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059271	A2	20030724	WO 2003-US1099	20030114
WO 2003059271	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003220374	A1	20031127	US 2003-341174	20030113
CA 2472199	AA	20030724	CA 2003-2472199	20030114
AU 2003207557	A1	20030730	AU 2003-207557	20030114
AU 2003207557	A2	20030730		
EP 1465621	A2	20041013	EP 2003-705768	20030114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642544	A	20050720	CN 2003-805886	20030114
BR 2003006872	A	20050906	BR 2003-6872	20030114
JP 2006501136	T2	20060112	JP 2003-559436	20030114
ZA 2004005562	A	20051004	ZA 2004-5562	20040713
PRIORITY APPLN. INFO.:			US 2002-348298P P	20020114
			US 2003-341174 A	20030113
			WO 2003-US1099 W	20030114

OTHER SOURCE(S): MARPAT 139:111706

AB Methods for the treatment, prevention, or inhibition of pain, inflammation, or inflammation-related disorder, and for the treatment or inhibition of a cardiovascular disease or disorder, and for the treatment or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor-α agonist and a cyclooxygenase-2 selective inhibitor (e.g. celecoxib; preparation described), or prodrug thereof. Compns., pharmaceutical compns., and kits for effecting the particular methods are also described.

L8 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:551339 CAPLUS
DOCUMENT NUMBER: 139:95464
TITLE: Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
INVENTOR(S): Macmillan, Stephen P.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057166	A2	20030717	WO 2003-US255	20030107
WO 2003057166	A3	20031106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2471951	AA	20030717	CA 2003-2471951	20030107
AU 2003207453	A1	20030724	AU 2003-207453	20030107
AU 2003207453	A2	20030724		
US 2003143271	A1	20030731	US 2003-337583	20030107
US 2003207846	A1	20031106	US 2003-337760	20030107
EP 1469846	A2	20041027	EP 2003-705660	20030107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003006777	A	20050426	BR 2003-6777	20030107
CN 1638760	A	20050713	CN 2003-805349	20030107
JP 2005524618	T2	20050818	JP 2003-557525	20030107
ZA 2004005379	A	20050617	ZA 2004-5379	20040706
PRIORITY APPLN. INFO.:			US 2002-346560P P	20020107
			WO 2003-US255 W	20030107

AB A method for the prevention, treatment, or amelioration of pain, inflammation, or inflammation-related disorder in a subject that is in need of such prevention, treatment or amelioration, involves the administration to the subject of a cyclooxygenase-2 selective inhibitor or prodrug thereof and enteric-coated aspirin. A method can also involve the administration of a cyclooxygenase-2 selective inhibitor and aspirin in an amount lower than 75 mg/day. A method can also involve the administration of a cyclooxygenase-2 selective inhibitor and aspirin where the cyclooxygenase-2 selective inhibitor is BMS-347070, S-33516, CS-502, darbufelone, LAS 34475, LAS 34556, L-745337, SD-8381, RWJ-63556, L-784512, COX-189, ABT-963, or valdecoxib, or any pharmaceutical salt or prodrug thereof. Compns., pharmaceutical compns., and kits that can be used with the methods are also described. Preparation of celecoxib is described.

L8 ANSWER 36 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2003:532347 CAPLUS
DOCUMENT NUMBER:	139:79173
TITLE:	Methods and compositions using a cyclooxygenase 2 (COX-2) inhibitor for the treatment of psychiatric disorders
INVENTOR(S):	Muller, Norbert
PATENT ASSIGNEE(S):	Germany
SOURCE:	U.S. Pat. Appl. Publ., 27 pp. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2003130334	A1	20030710	US 2002-157969	20020531
EP 1627639	A2	20060222	EP 2005-24864	20020531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2006167074	A1	20060727	US 2005-320757	20051230
PRIORITY APPLN. INFO.:			DE 2001-10129328	A 20010619
			US 2002-364904P	P 20020314
			DE 2001-10129320	A 20010619
			EP 2002-738138	A3 20020531
			US 2002-157969	A2 20020531

OTHER SOURCE(S): MARPAT 139:79173

AB A method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia, is described which comprises administering a COX-2 inhibitor, or prodrug thereof, to a subject. Moreover, a method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia or a depressive disorder, is disclosed, comprising administering to a subject a COX-2 inhibitor or prodrug thereof in combination with a neuroleptic drug or an antidepressant. Compns. and kits that are suitable for the practice of the method are also described.

L8 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:492716 CAPLUS
DOCUMENT NUMBER: 139:63316
TITLE: Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
INVENTOR(S): Masferrer, Jaime L.; Cherrington, Julie M.; Leahy, Kathleen M.; Zweifel, Ben S.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of Appl. No. PCT/US99/30693.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 21
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003119895	A1	20030626	US 2002-150546	20020516
WO 2000038730	A2	20000706	WO 1999-US30693	19991222
WO 2000038730	A3	20001102		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1522313	A1	20050413	EP 2004-26577	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY				
CA 2484324	AA	20031127	CA 2003-2484324	20030515
WO 2003097044	A1	20031127	WO 2003-US15582	20030515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003239494	A1	20031202	AU 2003-239494		20030515
BR 2003010027	A	20050215	BR 2003-10027		20030515
EP 1509224	A1	20050302	EP 2003-734058		20030515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005530781	T2	20051013	JP 2004-505043		20030515
AU 2004210578	A1	20041007	AU 2004-210578		20040910
PRIORITY APPLN. INFO.:			US 1998-113786P	P	19981223
			WO 1999-US30693	A2	19991222
			US 1999-385214	A	19990827
			AU 2000-25936	A3	19991222
			EP 1999-968939	A3	19991222
			US 2002-150546	A	20020516
			WO 2003-US15582	W	20030515

OTHER SOURCE(S): MARPAT 139:63316

AB The invention provides methods and compns. useful for treatment or prevention of neoplasia by administering a combination comprising a 3-heteroaryl-2-indolinone compound (preparation included) and a COX-2 selective inhibitor. Further provided are compns., pharmaceutical compns., and kits for treatment and prevention of neoplasia.

L8 ANSWER 38 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:154262 CAPLUS
DOCUMENT NUMBER: 138:198610
TITLE: Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
INVENTOR(S): Pulaski, Steven P.; Kundel, Susan
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015799	A1	20030227	WO 2002-US25673	20020813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003114416	A1	20030619	US 2002-215539	20020809
CA 2457452	AA	20030227	CA 2002-2457452	20020813
AU 2002336344	A2	20030303	AU 2002-336344	20020813
EP 1416941	A1	20040512	EP 2002-773188	20020813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002011977	A	20040921	BR 2002-11977		20020813
JP 2005501850	T2	20050120	JP 2003-520758		20020813
CN 1575182	A	20050202	CN 2002-820121		20020813
ZA 2004001163	A	20050622	ZA 2004-1163		20040212
PRIORITY APPLN. INFO.:			US 2001-312211P	P	20010814
			US 2002-215539	A	20020809
			WO 2002-US25673	W	20020813

OTHER SOURCE(S): MARPAT 138:198610

AB A method of treating, preventing, or inhibiting pain, inflammation, or inflammation-associated disorder in a subject in need of such treatment or prevention includes treating the subject with chondroitin sulfate and a cyclooxygenase-2 selective inhibitor, or a prodrug thereof, wherein the amount of chondroitin sulfate and the amount of a cyclooxygenase-2 selective inhibitor or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain- or inflammation-suppressing treatment or prevention effective amount Glucosamine can optionally be present. Compns. that contain the combination of chondroitin sulfate and cyclooxygenase-2 selective inhibitor and, optionally, the glucosamine, are disclosed, as are pharmaceutical compns.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 39 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:154260 CAPLUS

DOCUMENT NUMBER: 138:198609

TITLE: Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine

INVENTOR(S): Pulaski, Steven P.; Kundel, Susan

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015797	A1	20030227	WO 2002-US25674	20020813
WO 2003015797	C1	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003114418	A1	20030619	US 2002-215816	20020809
CA 2457453	AA	20030227	CA 2002-2457453	20020813
AU 2002331076	A2	20030303	AU 2002-331076	20020813
EP 1416940	A1	20040512	EP 2002-768522	20020813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011936	A	20041026	BR 2002-11936	20020813

JP 2005507871	T2	20050324	JP 2003-520756	20020813
CN 1767835	A	20060503	CN 2002-820216	20020813
ZA 2004001158	A	20050622	ZA 2004-1158	20040212
PRIORITY APPLN. INFO.:			US 2001-312272P P	20010814
			US 2002-215216 A	20020809
			US 2002-215816 A	20020809
			WO 2002-US25674 W	20020813

OTHER SOURCE(S): MARPAT 138:198609

AB A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with glucosamine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of glucosamine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount of the composition Compns. and pharmaceutical compns. that contain glucosamine and a cyclooxygenase-2 selective inhibitor are also disclosed.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:154230 CAPLUS

DOCUMENT NUMBER: 138:210277

TITLE: Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies

INVENTOR(S): Diamond, Scott L.; Gruneich, Jeffrey

PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA

SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015757	A1	20030227	WO 2002-US26152	20020815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2456977	AA	20030227	CA 2002-2456977	20020815
EP 1424998	A1	20040609	EP 2002-759383	20020815
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005525290	T2	20050825	JP 2003-520717	20020815
US 2005069577	A1	20050331	US 2004-777805	20040212
PRIORITY APPLN. INFO.:			US 2001-312729P P	20010816
			US 2002-358138P P	20020220
			WO 2002-US26152 W	20020815

AB The invention relates to compns. and methods for a one-step synthetic technique for making cationic steroid or cationic drug mols. for use as delivery vehicles. The invention further relates to methods for using

cationic steroid mols. in lipofection or transfection, delivery of drugs, and for treatment of inflamrnation and other diseases and disorders. The invention also relates to cationic steroid prodrugs and cationic prodrugs and to methods of modifying drugs.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 41 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:977588 CAPLUS
DOCUMENT NUMBER: 138:33362
TITLE: Use of cyclooxygenase 2 (COX-2) inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism, or tic disorders
INVENTOR(S): Muller, Norbert
PATENT ASSIGNEE(S): Germany
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102297	A2	20021227	WO 2002-EP6013	20020531
WO 2002102297	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10129320	A1	20030410	DE 2001-10129320	20010619
CA 2448025	AA	20021227	CA 2002-2448025	20020531
EP 1397145	A2	20040317	EP 2002-738138	20020531
EP 1397145	B1	20060906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534066	T2	20041111	JP 2003-504886	20020531
EP 1627639	A2	20060222	EP 2005-24864	20020531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004204469	A1	20041014	US 2004-480600	20040205

PRIORITY APPLN. INFO.:

DE 2001-10129320	A	20010619
US 2002-364904P	P	20020314
EP 2002-738138	A3	20020531
WO 2002-EP6013	W	20020531

OTHER SOURCE(S): MARPAT 138:33362

AB The invention discloses the use of a COX-2 inhibitor for the treatment of psychiatric disorders, e.g. schizophrenia, delusional disorders, affective disorders, autism or tic disorders, in particular chronic schizophrenic psychoses and schizoaffective psychoses, temporary acute psychotic disorders, depressive episodes, recurring depressive episodes, manic episodes and bipolar affective disorders. Moreover, the invention discloses the use of a COX-2 inhibitor, in particular celecoxib, in combination with a neuroleptic drug, in particular risperidone, or an

antidepressant, for the treatment of psychiatric disorders such as schizophrenia, delusional disorders, affective disorders, autism or tic disorders.

L8 ANSWER 42 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:927258 CAPLUS
DOCUMENT NUMBER: 138:16609
TITLE: Skin-permeable selective cyclooxygenase-2 inhibitor composition
INVENTOR(S): Lu, Guang Wei; Ewing, Gary D.; Tyle, Praveen; Stoller, Brenda M.; Gokhale, Rajeev; Gadre, Ashwini
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002096435	A2	20021205	WO 2002-US17067		20020530
WO 2002096435	A3	20030501			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2448627	AA	20021205	CA 2002-2448627		20020530
US 2003161867	A1	20030828	US 2002-158342		20020530
NZ 529797	A	20031219	NZ 2002-529797		20020530
EP 1404345	A2	20040407	EP 2002-774123		20020530
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002010104	A	20040608	BR 2002-10104		20020530
JP 2004532871	T2	20041028	JP 2002-592944		20020530
CN 1547474	A	20041117	CN 2002-814946		20020530
ZA 2003009298	A	20040512	ZA 2003-9298		20031128
PRIORITY APPLN. INFO.:			US 2001-294838P	P	20010531
			US 2001-350756P	P	20011113
			WO 2002-US17067	W	20020530

OTHER SOURCE(S): MARPAT 138:16609
AB A skin deliverable pharmaceutical composition comprises at least 1 selective cyclooxygenase-2 (COX-2) inhibitory drug or prodrug thereof solubilized in a pharmaceutically acceptable carrier that contains a low mol. weight monohydric alc., and exhibits a skin permeation rate of the therapeutic agent at least equal to that exhibited by a reference solution of the therapeutic agent in 70% aqueous ethanol. A method of effecting targeted delivery of a selective COX-2 inhibitory drug to a site of pain and/or inflammation in a subject comprises topically administering such a composition to skin of the subject, preferably at a locus overlying or adjacent to the site of pain and/or inflammation. A method of effecting systemic treatment of a subject having a COX-2 mediated disorder comprises transdermally administering such a composition, preferably by contacting the

composition with an area of skin of the subject ≥400 cm2. Thus, celecoxib was observed in 70% aqueous EtOH and this solution provided greater skin flux of the drug.

L8 ANSWER 43 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:556104 CAPLUS
DOCUMENT NUMBER: 137:109489
TITLE: Compositions comprising a polypeptide and an active agent
INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randal J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 20
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002099013	A1	20020725	US 2001-933708		20010822
US 2004087483	A1	20040506	US 2002-136433		20020502
US 2004063628	A1	20040401	US 2002-156527		20020529
US 7060708	B2	20060613			
US 2006014697	A1	20060119	US 2005-89056		20050325
PRIORITY APPLN. INFO.:			US 2000-247556P	P	20001114
			US 2000-247558P	P	20001114
			US 2000-247559P	P	20001114
			US 2000-247560P	P	20001114
			US 2000-247561P	P	20001114
			US 2000-247594P	P	20001114
			US 2000-247595P	P	20001114
			US 2000-247606P	P	20001114
			US 2000-247607P	P	20001114
			US 2000-247608P	P	20001114
			US 2000-247609P	P	20001114
			US 2000-247610P	P	20001114
			US 2000-247611P	P	20001114
			US 2000-247612P	P	20001114
			US 2000-247620P	P	20001114
			US 2000-247621P	P	20001114
			US 2000-247634P	P	20001114
			US 2000-247635P	P	20001114
			US 2000-247698P	P	20001114
			US 2000-247699P	P	20001114
			US 2000-247700P	P	20001114
			US 2000-247701P	P	20001114
			US 2000-247702P	P	20001114
			US 2000-247797P	P	20001114
			US 2000-247798P	P	20001114
			US 2000-247799P	P	20001114
			US 2000-247800P	P	20001114
			US 2000-247801P	P	20001114
			US 2000-247802P	P	20001114
			US 2000-247803P	P	20001114
			US 2000-247804P	P	20001114
			US 2000-247805P	P	20001114
			US 2000-247807P	P	20001114

US 2000-247832P	P	20001114
US 2000-247833P	P	20001114
US 2000-247926P	P	20001114
US 2000-247927P	P	20001114
US 2000-247928P	P	20001114
US 2000-247929P	P	20001114
US 2000-247930P	P	20001114
US 1999-265415	B2	19990310
US 1999-411238	B2	19991004
WO 2000-US5693	A	20000306
US 2000-642820	A2	20000822
US 2000-248607P	P	20001116
US 2000-248620P	P	20001116
US 2000-248656P	P	20001116
US 2000-248658P	P	20001116
US 2000-248659P	P	20001116
US 2000-248660P	P	20001116
US 2000-248662P	P	20001116
US 2000-248663P	P	20001116
US 2000-248685P	P	20001116
US 2000-248737P	P	20001116
US 2000-248738P	P	20001116
US 2000-248764P	P	20001116
US 2000-248767P	P	20001116
US 2000-248768P	P	20001116
US 2000-248769P	P	20001116
US 2000-248770P	P	20001116
US 2000-248771P	P	20001116
US 2000-248772P	P	20001116
US 2000-248774P	P	20001116
US 2000-248776P	P	20001116
US 2000-248777P	P	20001116
US 2000-248778P	P	20001116
US 2000-248779P	P	20001116
US 2000-248782P	P	20001116
US 2000-248787P	P	20001116
US 2000-248794P	P	20001116
US 2000-248795P	P	20001116
US 2000-248796P	P	20001116
US 2000-248797P	P	20001116
US 2001-933708	A2	20010822
US 2001-986426	A2	20011108
US 2001-987458	B2	20011114
WO 2001-US43089	B2	20011114
US 2001-988034	B2	20011116
US 2001-988071	B2	20011116
WO 2001-US43115	B2	20011116
WO 2001-US43117	B2	20011116
US 2002-358368P	P	20020222
US 2002-358381P	P	20020222
US 2002-362082P	P	20020307
US 2002-366258P	P	20020322
US 2002-156527	A2	20020529
WO 2003-US5525	A2	20030224
US 2003-507012P	P	20030930
US 2004-567800P	P	20040505
US 2004-567802P	P	20040505
US 2004-568011P	P	20040505
US 2004-923088	A2	20040823
US 2004-923257	A2	20040823

US 2004-953110	A2	20040930
US 2004-953111	A2	20040930
US 2004-953116	A2	20040930
US 2004-953119	A2	20040930
US 2004-955006	A2	20040930
WO 2004-US32131	A2	20040930

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalexin hydrochloride.

L8 ANSWER 44 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:392237 CAPLUS
DOCUMENT NUMBER: 136:401651
TITLE: Preparation of fused pyridine derivatives as HMG-CoA reductase inhibitors
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 875,218.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002061901	A1	20020523	US 2001-8154		20011204
US 6620821	B2	20030916			
US 2002028826	A1	20020307	US 2001-875218		20010606
US 2004024216	A1	20040205	US 2003-602753		20030624
PRIORITY APPLN. INFO.:			US 2000-211594P	P	20000615
			US 2001-875218	A2	20010606
			US 2001-8154	A3	20011204

OTHER SOURCE(S): MARPAT 136:401651
GI



I



II

AB The title compds. I and their pharmaceutically acceptable salts, esters, prodrug esters, and stereoisomers are claimed [wherein: Z = CH(OH)CH2CR7(OH)CH2CO2R3 or corresponding pyranone lactone derivs.; n = 0, 1; x = 0, 1, 2, 3, or 4; y = 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH2)x and/or (CH2)y together with addnl. carbons form a 3 to 7 membered spirocyclic ring; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H or lower alkyl; R4 = H, halo, CF3, OH, alkyl, alkoxy, CO2H, (un)substituted NH2, cyano, (un)substituted CONH2, etc.; R7 = H, alkyl]. The compds. are HMG-CoA reductase inhibitors, and are active in inhibiting cholesterol biosynthesis and modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol (no data). I are thus useful in treating hyperlipidemia and dyslipidemia, in hormone replacement therapy, and in treating hypercholesterolemia, hypertriglyceridemia and atherosclerosis, as well as Alzheimer's disease and osteoporosis. Prepns. of several compds. are described. For instance, a multistep synthesis of fused pyridine derivative II is reported. Compds. I may be used in a manner similar to atorvastatin, pravastatin, simvastatin, etc. Combinations of compds. I with various other drugs are claimed, the latter being specified as certain pharmacol. classes, as inhibitors of specific enzymes, as (ant)agonists of specific receptors, and as numerous named drugs.

L8 ANSWER 45 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:332011 CAPLUS
DOCUMENT NUMBER: 136:355482
TITLE: Compositions comprising a polypeptide and an active agent
INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randall J.
PATENT ASSIGNEE(S): New River Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 20
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034237	A1	20020502	WO 2001-US26142	20010822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6716452	B1	20040406	US 2000-642820	20000822
CA 2420590	AA	20020502	CA 2001-2420590	20010822
AU 2001086599	A5	20020506	AU 2001-86599	20010822
EP 1311242	A1	20030521	EP 2001-966056	20010822
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004523480	T2	20040805	JP 2002-537291	20010822
US 2004127397	A1	20040701	US 2003-727565	20031205
PRIORITY APPLN. INFO.:			US 2000-642820 A	20000822

US 2000-247613P	P	20001114
US 2000-247614P	P	20001114
US 2000-247615P	P	20001114
US 2000-247616P	P	20001114
US 2000-247617P	P	20001114
US 2000-247622P	P	20001114
US 2000-247630P	P	20001114
US 2000-247631P	P	20001114
US 2000-247632P	P	20001114
US 2000-247633P	P	20001114
US 2000-247556P	P	20001114
US 2000-247558P	P	20001114
US 2000-247559P	P	20001114
US 2000-247560P	P	20001114
US 2000-247561P	P	20001114
US 2000-247594P	P	20001114
US 2000-247595P	P	20001114
US 2000-247606P	P	20001114
US 2000-247607P	P	20001114
US 2000-247608P	P	20001114
US 2000-247609P	P	20001114
US 2000-247610P	P	20001114
US 2000-247611P	P	20001114
US 2000-247612P	P	20001114
US 2000-247620P	P	20001114
US 2000-247621P	P	20001114
US 2000-247634P	P	20001114
US 2000-247635P	P	20001114
US 2000-247698P	P	20001114
US 2000-247699P	P	20001114
US 2000-247701P	P	20001114
US 2000-247702P	P	20001114
US 2000-247797P	P	20001114
US 2000-247798P	P	20001114
US 2000-247799P	P	20001114
US 2000-247800P	P	20001114
US 2000-247801P	P	20001114
US 2000-247802P	P	20001114
US 2000-247803P	P	20001114
US 2000-247804P	P	20001114
WO 2001-US26142	W	20010822

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalexin hydrochloride.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 46 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:327387 CAPLUS
DOCUMENT NUMBER: 137:332985
TITLE: Superior analgesic effect of loxoprofen Na, a prodrug of a non-selective COX inhibitor, over COX-2 selective inhibitors in rats
AUTHOR(S): Makino, Mitsuko; Kojima, Takayoshi; Hayakawa, Makiko; Hiramoto, Kumiko; Mori, Masayoshi
CORPORATE SOURCE: International Product Management & Medical Affairs

Department, Sankyo Co., Ltd., Tokyo, 103-8426, Japan
SOURCE: Annual Report of Sankyo Research Laboratories (2001), 53, 103-108
CODEN: ASRLEC; ISSN: 1341-741X
PUBLISHER: Sankyo Co., Ltd., Research Institute
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The analgesic effect of loxoprofen Na, a prodrug of a non-selective COX inhibitor, was compared with indomethacin, a non-selective COX inhibitor, and selective COX-2 inhibitors such as celecoxib, rofecoxib and meloxicam by using the Randall-Selitto method in rats. Loxoprofen Na suppressed pain sensation at doses of 0.13 mg/kg and higher, while indomethacin, celecoxib, rofecoxib and meloxicam suppressed this at doses of 8.4, 0.98, 2.4 and 18.3 mg/kg, resp., and higher. Judging from the min. EDs, loxoprofen Na seems to have 7-140 times more potent analgesic action than the selective COX-2 inhibitors and indomethacin. Furthermore, the analgesic activity of loxoprofen Na appeared 15 min after oral administration, which was the shortest latency among the NSAIDs examined Although loxoprofen Na is a prodrug, its rapid oral absorption and conversion to the active form (trans-OH metabolite), which have been already reported, would explain the short latency to the appearance of its analgesic action. This is the first manuscript to report comparison of the analgesic action of a prodrug of a non-selective COX inhibitor with that of selective COX-2 inhibitors in rats. The present data indicates that the analgesic effect of loxoprofen Na is superior to the COX-2 selective inhibitors examined

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 47 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:276519 CAPLUS
DOCUMENT NUMBER: 136:310188
TITLE: Treatment of cancer with a prostate specific antigen (PSA) conjugate and an NSAID compound
INVENTOR(S): Heimbrook, David C.; Yao, Siu-long
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 129 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002042375	A1	20020411	US 2001-896245		20010629
PRIORITY APPLN. INFO.:			US 2000-216217P	P	20000705

OTHER SOURCE(S): MARPAT 136:310188

AB The invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a nonsteroidal antiinflammatory agent (NSAID) and to methods of preparing such compns. The PSA conjugate comprises an oligopeptide that is selectively cleaved by PSA and a cytotoxic agent. An example of a PSA conjugate is N-Ac-(4-trans-L-Hyp)-Ala-Ser-Chg-Gln-Ser-Leu-Dox (Dox = doxorubicin, Hyp = hydroxyproline, Chg = cyclohexylglycine) and COX-2 inhibitor 3-phenyl-4-[4-(4-methylsulfonyl)phenyl]-2(5H)furanone is an example of an NSAID compound (syntheses given).

L8 ANSWER 48 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:10616 CAPLUS
DOCUMENT NUMBER: 134:91125
TITLE: Pharmaceutical compositions containing aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
INVENTOR(S): Mylari, Banavara Lakshman
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 103 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1064965	A2	20010103	EP 2000-305361	20000626
EP 1064965	A3	20030212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6555540	B1	20030429	US 2000-602419	20000623
JP 2001031569	A2	20010206	JP 2000-194053	20000628
CA 2313063	AA	20001230	CA 2000-2313063	20000629
BR 2000002957	A	20010130	BR 2000-2957	20000630
PRIORITY APPLN. INFO.:			US 1999-141695P P	19990630

OTHER SOURCE(S): MARPAT 134:91125
AB Pharmaceutical compns. containing aldose reductase inhibitors, a prodrug thereof or a salts and and selective cyclooxygenase-2 inhibitors, a prodrug thereof or salts thereof are disclosed. The compns. are used for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy and diabetic cardiomyopathy. Hard gelatin capsules contained active ingredients 0.25-100, starch 0.o-650, starch powder 0.o-50, and silicone fluid 350-cSt 0.15 mg/capsules.

L8 ANSWER 49 OF 49 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:202670 CAPLUS
DOCUMENT NUMBER: 128:266249
TITLE: Diphenyl stilbenes as prodrugs to cyclooxygenase-2 inhibitors, pharmaceutical compositions, and preparation thereof
INVENTOR(S): Black, Cameron; Girard, Mario; Guay, Daniel; Wang, Zhaoyin
PATENT ASSIGNEE(S): Merck Frosst Canada, Inc., Can.
SOURCE: U.S., 21 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5733909	A	19980331	US 1997-784663	19970121
PRIORITY APPLN. INFO.:			US 1997-784663	19970121

OTHER SOURCE(S): MARPAT 128:266249
GI



I

AB Compds. I [X = CH2OH, CHO, CO2R4, CONR42; Y = Me, CH2OR5; R1 = S(O)2Me, S(O)2NH2, etc.; R2, R3 = H, halo, C1-6 alkoxy, etc.; R4 = H, C1-6 alkyl, etc.; R5 = C1-6 alkyl, (substituted) benzyl] are disclosed for the treatment of cyclooxygenase-2 mediated diseases. Also disclosed are pharmaceutical compns. containing I for treatment of cyclooxygenase-2 mediated diseases. Compds. of the invention are useful for treating inflammatory diseases susceptible to treatment with a nonsteroidal antiinflammatory agent. Preparation of selected I is described.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	137.54	332.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-36.75	-39.75

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:49:01 ON 18 SEP 2006